Axsome Therapeutics Inc
19X
Company Profile
Business description
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Contact
One World Trade Center
22nd Floor
New YorkNY10007
USAT: +1 212 332-3241
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
589
Stocks News & Analysis
stocks
Acquisition a sign of weakness for overvalued ASX share
Acquisition unlikely to improve prospects in the US and detracts from other opportunities.
stocks
3 global ‘buy the dip’ candidates with wide moats
Does recent share price weakness spell opportunity in these three high-quality companies? Our analysts think so.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,120.90 | 34.10 | 0.38% |
| CAC 40 | 7,896.93 | 71.69 | 0.92% |
| DAX 40 | 23,748.86 | 50.71 | 0.21% |
| Dow JONES (US) | 45,829.38 | 4.84 | -0.01% |
| FTSE 100 | 9,277.03 | 6.26 | -0.07% |
| HKSE | 26,446.56 | 58.40 | 0.22% |
| NASDAQ | 22,313.59 | 172.49 | 0.78% |
| Nikkei 225 | 44,768.12 | 395.62 | 0.89% |
| NZX 50 Index | 13,208.31 | 19.59 | -0.15% |
| S&P 500 | 6,608.67 | 24.38 | 0.37% |
| S&P/ASX 200 | 8,853.00 | 31.60 | 0.36% |
| SSE Composite Index | 3,860.50 | 10.09 | -0.26% |